New study tracks risks of combining lung cancer treatments
NCT ID NCT03705806
First seen Mar 07, 2026 · Last updated Apr 28, 2026 · Updated 4 times
Summary
This study observes 12 people with stage IV non-small cell lung cancer who are already receiving immunotherapy (nivolumab or pembrolizumab) and also need palliative radiation to the chest. The goal is to track side effects from the combination and how it affects quality of life. Participants receive standard radiation (30 Gy in 10 sessions) and are followed for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.